 |
Sitemap
|
|
|
| |
 |
|
|
|
|
|
|
HOME > Investor Information > FAQs
 What is your stock code? |
 |
It is 2784. |
|
| Does the company offer shareholder perks? |
|
No, we do not currently do so. |
|
| Please tell us about the company’s dividend policy and dividend payment. |
|
The company targets an annual dividend on equity of 2% or more with the exact rate to be determined based on the consolidated financial results, while taking into consideration the stability of its management base, future business expansion and other factors. Under this policy, the company paid an annual dividend of 87 per-share for the year ended March 31, 2009, including a 45 interim dividend. The planned annual dividend for the year ending March 31, 2010 is 88 yen including a 44 year-end dividend. |
|
| When is the general shareholders meeting held? |
|
In June every year. For 2009, we held the meeting on June 25. |
| When was the company established? |
|
On September 29, 2003. |
|
| When did the company list its shares? |
|
With its establishment on September 29, 2003, the company was listed on the first section of the Tokyo Stock Exchange and the Osaka Securities Exchange. |
|
| Please share with us how Alfresa Holdings Corporation was established. |
|
To use management resources effectively and efficiently, AZWELL Inc. and Fukujin Co., Ltd. established the company as a joint holding company. |
|
| What is the origin of the corporate name "Alfresa"? |
|
Alfresa is a compound word consisting of the English word "all" and an Esperanto word "fresa" which means "fresh" in English. Please see origin of the corporate name. |
|
| Please tell us about the company’s medium-term management policy. |
|
The Alfresa Group has formulated “07-09 Medium-term Management Plan ― Advancement and Expansion” covering the three-year period from April 1, 2007 to March 31, 2010. We target management benchmark of an ROE, ROA, and equity ratio of 9%, 2% and 23% or more, respectively, for the fiscal year ending March 31, 2010, the plan’s final year. In addition, as medium- to long-term management strategies and priorities, we aim to “expand the wholesaling business of pharmaceuticals, etc. and pursue group synergy effects,” “solidify the business base of the manufacturing of pharmaceuticals, etc.,” “realize Healthcare Consortium” and “enhance the group management base and strengthen the administration system.” |
|
| When is your accounting period? |
|
The closing of the books for the full term is on March 31 every year. For future schedules, please see "IR Calendar." |
| Where can I find the previous IR materials? |
|
Financial statements are available under "Financial Statements" as well as annual reports, materials for financial results briefings and medium-term management plans, and press releases are "Annual Reports," "Presentations," and "News Release," respectively. |
|
| Where can we check on changes in net sales and ordinary profit? |
|
Please click here. |
| What kind of products do the subsidiaries deal in? |
|
In the wholesaling business, we wholesale ethical pharmaceuticals prescribed at hospitals and clinics, diagnostic reagents such as used in laboratories of medical institutions, and medical devices including X-ray machines and MRI machines.
In the manufacturing business, we manufacture, sell, and import and export products. In pharmaceuticals, we are focusing on developing products centering on central nervous system and dermatology fields. In diagnostic reagents, we are focusing on POCT (point-of-care testing) reagents (rapid diagnostic reagents) and fecal occult blood test agents. With medical devices, we handle surgical sutures, various types of nebulizers and other products.
|
|
|
|